<DOC>
	<DOCNO>NCT02749630</DOCNO>
	<brief_summary>This study randomize , observer-blinded , placebo-controlled study evaluate safety , tolerability , immunogenicity , pharmacokinetics repeat dose intravenous ( IV ) UTTR1147A . The study consist repeat dose escalation healthy volunteer ( HV ) repeat dose escalation Ulcerative Colitis ( UC ) patient across multiple site .</brief_summary>
	<brief_title>A Safety Study Intravenously Administered UTTR1147A Healthy Volunteers Patients With Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>General inclusion criterion : No history malignancy documentation ageappropriate cancer screen For woman childbearing potential : agreement remain abstinent use contraceptive method For men : agreement remain abstinent use contraceptive measure agreement refrain donate sperm For Healthy Volunteers Only : Age 18 50 Body mass index ( BMI ) 18 32 kg/m2 , inclusive In good health clinically significant finding medical history , 12lead electrocardiogram ( ECG ) , vital sign Normal clinically significant laboratory result For Ulcerative Colitis Patients Only : Age 18 80 Eligible receive biologic therapy Disease duration &gt; / = 12 week Diagnosis moderate severe ulcerative colitis General exclusion criterion : History inflammatory skin disorder History cancer History anaphylaxis , hypersensitivity , drug allergy History alcoholism drug addiction Positive test indicate infection hepatitis C , hepatitis B , HIV Use nonbiologic investigational drug participation investigational study nonbiologic drug within 30 day prior study drug administration Use biologic investigational therapy participation investigational study involve biologic therapy within 90 day 5 halflives History presence abnormal ECG clinically significant Any acute chronic condition would limit subject 's ability complete and/or participate clinical study Pregnant lactating , intend become pregnant duration study For HV Only : Known family history gastrointestinal ( GI ) and/or colon cancer Prior exposure UTTR1147A For UC Patients Only : Significant uncontrolled comorbidity , neurological , cardiac , pulmonary , renal , hepatic , endocrine , gastrointestinal ( GI ) disorder History Primary Sclerosing Cholangitis Active antiTNF induce psoriasiform eczematous lesion Moderate severe anemia Presence ileostomy colostomy Total proctocolectomy Positive screen test latent mycobacterial tuberculosis infection Impaired renal function Impaired hepatic function</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>